

REVIEW

Open Access



The next frontier in immunotherapy: potential and challenges of CAR-macrophages

Jing Li¹, Ping Chen² and Wenxue Ma^{3*}

Abstract

Chimeric antigen receptor macrophage (CAR-M Φ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-M Φ offers a promising approach to target and eradicate tumor cells by utilizing macrophages' phagocytic and antigen-presenting abilities. However, challenges such as the complex tumor microenvironment (TME), variability in antigen expression, and immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of CAR-M Φ action, optimal construct designs, and interactions within the TME. It also delves into the ex vivo manufacturing challenges of CAR-M Φ , discussing autologous and allogeneic sources and the importance of stringent quality control. The potential synergies of integrating CAR-M Φ with existing cancer therapies like checkpoint inhibitors and conventional chemotherapeutics are examined to highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways for CAR-M Φ therapies are scrutinized alongside established protocols for CAR-T cells, identifying unique considerations essential for clinical trials and market approval. Proposed safety monitoring frameworks aim to manage potential adverse events, such as cytokine release syndrome, crucial for patient safety. Consolidating current research and clinical insights, this review seeks to refine CAR-M Φ therapeutic applications, overcome barriers, and suggest future research directions to transition CAR-M Φ therapies from experimental platforms to standard cancer care options.

Highlights

- CAR-M Φ offers an innovative approach to treating solid tumors, addressing the limitations of traditional CAR-T therapies.
- CAR-M Φ eliminates tumor cells and boosts other immune cells' effectiveness.
- Strategies are being developed to improve CAR-M Φ targeting and cancer cell eradication.
- CAR-M Φ is combined with other treatments to enhance overall efficacy.
- Challenges and safety concerns, including side effects of CAR-M Φ therapies, are being addressed.

Keywords CAR macrophage (CAR-M Φ), Immunotherapy, Tumor Microenvironment (TME), Combination therapies, Clinical trials

*Correspondence:

Wenxue Ma
wma@health.ucsd.edu

¹The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China

²Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Union Hospital, Fujian Medical University Fuzhou, Fujian 350001, China

³Sanford Stem Cell Institute, Moores Cancer Center, University of California San Diego, CA 92093 La Jolla, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Immunotherapy has revolutionized cancer treatment by leveraging the body's immune system to detect and eradicate malignant cells [1]. The field has seen substantial advancements over the past decade with the emergence of immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer therapies, each contributing to a significant shift in oncological therapeutic strategies [2–4]. Among these innovations, Chimeric Antigen Receptor T-cells (CAR-T) and Natural Killer cells (CAR-NK) represent breakthrough therapies [5, 6]. CAR-T cell therapy has shown exceptional efficacy in treating hematologic malignancies by reprogramming T cells to target and destroy tumor cells specifically [5]. Although CAR-NK therapies are still in the experimental stages, they have shown promise in offering similar therapeutic benefits but with potentially fewer adverse effects, such as cytokine release syndrome (CRS) and graft-versus-host disease (GVHD), which are more common in CAR-T cell treatments [7–10].

However, applying these cellular therapies to solid tumors has been fraught with challenges [5, 11]. The primary obstacles include the immunosuppressive nature of the tumor microenvironment (TME), the heterogeneity of tumor antigens, and physical barriers that restrict cellular infiltration into tumors [12–14]. These challenges have sparked significant debate and exploration within the research community, as there is a consensus that overcoming these barriers could unlock new therapeutic potentials for solid tumors [15, 16].

CAR macrophages (CAR-M Φ) may offer strategic benefits in reshaping the TME and triggering a comprehensive immune response due to their phagocytic nature and antigen-presentation capabilities, which could lead to more sustained tumor control [17]. This contentious backdrop has led to exploring CAR-M Φ as a novel therapeutic avenue. Macrophages, known for their roles in tissue homeostasis, inflammation, and immune surveillance, are engineered to express chimeric antigen receptors [18, 19]. This approach aims to harness their inherent phagocytic nature and ability to modulate the TME, positioning them as potentially effective agents in combating solid tumors [20–22]. Despite the theoretical benefits, considerable controversy exists regarding the efficacy, safety, and practical application of CAR-M Φ [22, 23]. Current knowledge is limited, particularly in direct clinical outcomes and mechanistic understanding of CAR-M Φ actions within varied TMEs [13, 24, 25].

Structural details and potential synergy with checkpoint inhibitors

Structural details of CAR-M Φ

The structure of CAR-M Φ is crucial for their function and therapeutic efficacy. CAR-M Φ are typically

engineered to express CARs that include an extracellular antigen-binding domain derived from an antibody's single-chain variable fragment (scFv). This domain is linked to intracellular signaling domains, which are crucial for activating macrophages upon antigen engagement [26]. These signaling domains often include co-stimulatory molecules such as CD28 or 4-1BB, which enhance macrophage survival, proliferation, and phagocytic efficacy [8, 19].

Potential synergy with checkpoint inhibitors

CAR-M Φ therapy's potential synergy with checkpoint inhibitors is a promising avenue for enhancing anti-tumor efficacy. Checkpoint inhibitors, such as those targeting PD-1/PD-L1 and CTLA-4 pathways, block inhibitory signals that dampen immune responses, thereby reactivating T cells to attack tumors [27, 28]. Combining CAR-M Φ with checkpoint inhibitors aims to overcome the immunosuppressive TME, thus enhancing the overall therapeutic outcome [29]. Recent studies have demonstrated the synergy between CAR-M Φ and checkpoint inhibitors. Yang et al. found that CAR-M Φ engineered with anti-PD-L1 scFv showed enhanced anti-tumor efficacy in preclinical models [30]. Harrasser et al. reported that localized delivery of an anti-PD-1 scFv boosts the antitumor activity of ROR1 CAR-T cells in triple-negative breast cancer (TNBC) [31]. Li et al. showed that combining CAR-M Φ with anti-CTLA-4 therapy enhances tumor cell phagocytosis and promotes a robust immune response [32].


Clinical efficacy and safety

Clinical evidence


The clinical exploration of CAR-M Φ is rapidly progressing, particularly for solid tumors where traditional CAR-T therapies face significant challenges [16, 18, 33, 34]. Current clinical trials primarily focus on assessing CAR-M Φ 's efficacy in reducing tumor mass and evaluating their safety for patients who have exhausted conventional treatments. Initial findings show CAR-M Φ can effectively localize to and persist within tumor sites, providing promising insights for ongoing and future research [18, 35]. However, comprehensive outcome data and extended follow-up are needed to understand CAR-M Φ 's long-term efficacy and safety [36].

One ongoing clinical trial, NCT04660929, is a Phase I study evaluating CAR-M Φ for treating HER2-overexpressing solid tumors. This trial includes patients with various HER2-positive cancers, such as breast, bladder, and lung cancers, and focuses on assessing the safety and preliminary efficacy of CAR-M Φ . Initial findings have shown that CAR-M Φ therapy is safe and well-tolerated, with some indications of anti-tumor activity, including tumor regression and enhanced T-cell infiltration at the


A. Clinical Trials Overview



B. Mechanisms of Action in the TME



C. Mechanism differences between CAR-M, CAR-T, and CAR-NK in killing solid tumors



D. Safety Profile




Fig. 1 (See legend on next page.)

(See figure on previous page.)

Fig. 1 Overview of CAR Cell Therapies: Clinical Trials, TME Interaction, and Safety Profiles. **(A)** Clinical Trials Overview: This panel illustrates the stages of clinical trial progression for CAR cell therapies, from pre-clinical lab research to Phase IV, detailing the evaluation of treatment effects in humans, safety and efficacy assessments, and the long-term impact of treatments. **(B)** Mechanisms of Action in the TME: Diagram displaying the diverse cellular composition and cytokine environment of the TME. The relationships and influences between different cell types and secreted cytokines are highlighted, showing the dynamic interactions within the TME that impact therapy outcomes. **(C)** Mechanism Differences between CAR-M Φ , CAR-T, and CAR-NK in Killing Solid Tumors: This segment compares the functional approaches of CAR-M Φ , CAR T-cells, and CAR natural killer cells (CAR-NK) in combating solid tumors, emphasizing the unique mechanisms like phagocytosis by CAR-M Φ , antigen-specific T cell activation by CAR-T, and direct cytotoxicity along with antibody-dependent cellular cytotoxicity (ADCC) by CAR-NK. **(D)** Safety Profile: Outlines the critical safety concerns associated with CAR cell therapies, including CRS, neurotoxicity (ICANS), and macrophage activation syndrome (MAS). The panel describes the progression of CRS symptoms from mild to severe, details the cellular and molecular processes involved in ICANS, and explains the various macrophage polarization states in MAS, along with their associated cytokines

tumor site [37]. However, extended follow-up is necessary to determine this therapeutic approach's long-term benefits and potential risks.

Preclinical studies have demonstrated CAR-M Φ 's unique capabilities, particularly their ability to modulate the complex TME, supporting immune-mediated tumor destruction [17, 19]. These studies have shown that CAR-M Φ not only directly attacks tumor cells but also transforms the typically suppressive TME into a more active, anti-tumor environment [34, 38]. By secreting pro-inflammatory cytokines and chemokines, CAR-M Φ recruits and activates other immune cells, suggesting a significant role in enhancing the efficacy of combination immunotherapies [30, 39].

Safety profile

The development and advancement of CAR-M Φ therapies bring promising therapeutic opportunities and significant safety considerations that mirror those observed with CAR-T cell therapies [40]. Both are known for their potential to cause severe adverse effects such as CRS and neurotoxicity due to their robust cytokine production capabilities [41, 42]. However, macrophages' intrinsic regulatory functions in managing inflammation suggest CAR-M Φ might control cytokine release more effectively, underscoring the need for research into their unique cytokine dynamics [43, 44].

CRS is a critical concern previously well-documented in CAR-T therapy, manifesting as a systemic inflammatory response that leads to life-threatening [5, 45, 46]. Similar risks are possible with CAR-M Φ therapies [19]. However, the distinct role of macrophages in cytokine regulation may result in different CRS dynamics, necessitating tailored strategies for anticipation, monitoring, and management [34, 42]. Recent studies suggest that engineering CAR-M Φ to express IL-10 can mitigate CRS while maintaining anti-tumor efficacy [19, 47].

Another safety concern is hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), involving excessive immune activation and organ damage [48, 49]. This is particularly relevant to CAR-M Φ therapies due to their role in these conditions [50, 51]. Ongoing vigilance in monitoring engineered cell

activation and inflammatory responses is crucial to prevent HLH/MAS.

Significant gaps remain in understanding how risks from CAR-T therapies translate to CAR-M Φ therapies [38, 52]. Questions include how CAR-M Φ modulates cytokine output and whether this modulation can be controlled to prevent adverse effects like CRS [33, 39, 53]. Furthermore, the long-term implications of CAR-M Φ therapy, especially concerning potential chronic inflammation or immune dysregulation, and the specificity of CAR-M Φ targeting to minimize off-target effects, need further exploration [54].

Comprehensive preclinical and clinical research on the unique safety dynamics of CAR-M Φ therapies is essential [17, 19, 34]. Developing accurate monitoring protocols and effective management strategies for potential adverse effects is imperative. Moreover, a deeper understanding of CAR-M Φ interactions with the immune system is crucial for maximizing therapeutic potential, mitigating risks, and integrating CAR-M Φ therapies into clinical oncology practice [51, 55].

Figure 1 below provides a detailed representation of the essential progression, intricate dynamics within the TME, and critical safety considerations associated with CAR cell therapies.

Recommendations for further research

As the potential of CAR-M Φ therapies unfolds, a comprehensive understanding of their clinical implications, particularly regarding safety and efficacy, is essential [39, 56]. Insights from current clinical trials are invaluable, yet they also highlight substantial gaps in understanding, especially concerning long-term impacts and broader applicability across various cancer types [18, 37].

Expanding the scope of clinical trials is crucial for thoroughly assessing the therapeutic potential and safety profile of CAR-M Φ across a broader spectrum of cancer types [57]. This expansion involves increasing the number of trials and including a diverse range of participants to explore how different demographics respond to CAR-M Φ therapy. Additionally, investigating CAR-M Φ interactions with other cancer treatments, such as chemotherapy or immunotherapy, could provide

Table 1 Advantages and limitations of CAR-T, CAR-NK, and CAR-M Φ therapies

Therapy Type	Advantages	Limitations
CAR-T	1 High Specificity: Highly effective in targeting specific antigens, particularly in hematologic cancers. 2 Established Protocols: Well-established clinical protocols and substantial clinical data.	1 TME Challenges: Limited efficacy in solid tumors due to immunosuppressive TME and T-cell exhaustion. 2 CRS and Neurotoxicity: Significant risks of severe adverse effects like CRS and neurotoxicity.
CAR-NK	1 Innate Cytotoxicity: Ability to kill tumor cells without prior sensitization. 2 Lower GVHD Risk: Lower risk of graft-versus-host disease (GVHD) compared to CAR-T cells.	1 Persistence and Expansion: Challenges in ensuring the persistence and expansion of CAR-NK cells within the TME. 2 Efficacy in Solid Tumors: Like CAR-T cells, CAR-NK cells face significant hurdles in solid tumors due to the TME.
CAR-M Φ	1 TME Modulation: CAR-M Φ can effectively remodel the TME to a more pro-inflammatory state, which is advantageous in solid tumors. 2 Antigen Presentation: Enhances the activation of T cells and overall immune response against tumors.	1 Phagocytic Efficiency: The efficiency of tumor cell engulfment in an immunosuppressive TME can be variable. 2 CRS: Potential risk of CRS, like CAR-T cells, though macrophages have intrinsic regulatory functions that might mitigate this risk.

insights into potential synergistic effects or complications [17, 58]. Experimenting with various CAR designs and administration strategies could also optimize the balance between efficacy and safety, improving the overall outcomes of CAR-M Φ therapies [56, 59].

There is also a pressing need for long-term follow-up studies to understand the sustained impact of CAR-M Φ treatments on patients. These studies are critical for evaluating the durability of therapeutic benefits, potential late-onset adverse effects, and overall quality of life post-treatment [60]. Understanding the long-term effects of CAR-M Φ therapy on the immune system, including possible impacts on immune memory and susceptibility to infections or other diseases, is vital [34, 61].

Despite promising advances in CAR-M Φ research, several significant controversies and unanswered questions remain. Debates continue over the best strategies for engineering and administering CAR-M Φ , focusing on maximizing efficacy while minimizing risks. The challenges of defining the optimal configuration of CAR constructs and the best delivery methods are compounded by significant regulatory and ethical questions, particularly regarding patient consent processes and trial inclusion criteria [62, 63].

To fully harness the therapeutic potential of CAR-M Φ and ensure their safe integration into clinical oncology, it is essential to expand clinical trials and conduct detailed long-term follow-up studies [64]. These efforts are crucial for filling current knowledge gaps and addressing broader controversies and challenges in the field. As research continues, these focused efforts will help pave the way for CAR-M Φ therapies to transition from experimental treatments to established options within the oncological arsenal, ensuring they are both practical and safe for clinical use [65].

Comparison with other CAR cells

CAR-T cells

CAR-T therapy has revolutionized the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) [64, 66]. This therapy targets and eliminates cancer cells with specific antigens, demonstrating significant efficacy. However, extending CAR-T therapy's success to solid tumors has proven complex, revealing intrinsic limitations that underscore the challenges of applying this therapy across diverse oncological applications [67, 68].

TME in solid tumors presents formidable physical and immunological barriers to CAR-T therapy [67, 69]. While CAR-T cells are highly effective in blood cancers, their application in solid tumors has not met with the same success due to the TME's complexity, which includes immunosuppressive cells, inhibitory cytokines like TGF- β and IL-10, and physical barriers that restrict CAR-T cell penetration and persistence [6, 13, 14]. Strategies to enhance CAR-T cell infiltration and survival within these hostile environments remain a significant focus of ongoing research [67, 70].

CAR-NK cells

CAR Natural Killer (CAR-NK) cells are rapidly emerging as a promising frontier in adoptive cell therapies, leveraging the innate capabilities of NK cells to recognize and eliminate malignant cells without prior sensitization [71]. By engineering these cells to express specific antigen receptors, researchers have expanded their targeting capabilities and enhanced their natural cytotoxic abilities, which include direct induction of cell death and release of cytolytic granules containing perforin and granzymes [72]. Additionally, CAR-NK cells can mediate ADCC, enhancing their utility against tumors that express specific antigens [73].

The clinical applications of CAR-NK cells have shown promising results, particularly in treating hematologic

malignancies such as leukemia and lymphoma [74]. However, translating these successes to solid tumors presents substantial challenges. The immunosuppressive TME in solid tumors can significantly inhibit CAR-NK cell function and persistence. In contrast, the heterogeneity of tumor antigens and the potential for antigen escape pose additional hurdles to their clinical effectiveness [10, 75, 76].

When compared with CAR-NK cells with CAR-M Φ , both modalities encounter similar challenges in solid tumors, particularly concerning immunosuppressive TME [10, 77]. However, CAR-NK cells may possess inherent advantages due to their cytotoxic mechanisms and ability to engage in ADCC, potentially providing a more robust and immediate response to tumor cells [78, 79].

CAR-M Φ

CAR-M Φ is making significant strides in adoptive cell therapy by utilizing the innate biological functions of macrophages to combat cancer [19, 30]. These engineered immune cells exploit macrophages' natural phagocytic and antigen-presenting abilities, offering a novel dimension in cancer treatment, particularly effective against solid tumors [19, 34]. The dual functionality of CAR-M Φ allows them to reduce tumor mass by engulfing and digesting tumor cells and to process and present antigens, thereby catalyzing a broader systemic immune response against the tumor [34].

Beyond their immediate impact on cancer cells, CAR-M Φ is adept at navigating and modulating the complex and often hostile TME [33, 80]. Their inherent migratory and infiltrative capabilities enable them to overcome physical barriers within the TME that typically shield tumor cells from immune attacks [13, 81]. Once inside the TME, CAR-M Φ can disrupt the local immunosuppressive conditions by secreting pro-inflammatory

cytokines and chemokines, making the environment more amenable to immune-mediated attack [36, 82].

Despite these significant advantages, CAR-M Φ faces several critical challenges that limit their broader application. The field widely recognizes the difficulty in identifying specific targets on tumor cells that can be consistently recognized by the engineered receptors on CAR-M Φ , given the heterogeneity of tumor cells and the potential for antigen escape mechanisms [17, 19]. This challenge underscores the ongoing debate over the specificity and efficacy of CAR-M Φ targeting and the need for continued research into universal tumor markers that CAR-M Φ can reliably target [83].

Moreover, like other CAR therapies, CAR-M Φ is at risk of inducing CRS, a severe side effect arising from cytokine's rapid release into the bloodstream [19]. This safety concern mirrors those associated with CAR-T therapies and fuels further debate on the clinical viability of CAR-M Φ [19]. Addressing this risk necessitates careful CAR construct design and strategies to control CAR-M Φ activity once administered to patients [17, 39].

To encapsulate the distinct characteristics and challenges faced by CAR-T, CAR-NK, and CAR-M Φ therapies in solid tumors, Table 2 offers a comparative overview, highlighting their respective advantages and limitations.

In conclusion, while CAR-M Φ offers unique advantages in cancer therapy through their phagocytic and antigen-presenting abilities and their capacity to modulate the TME, significant hurdles remain [33, 35]. The challenges of targeting specificity and managing CRS, along with unanswered questions about improving the specificity of CAR-M Φ for tumor cells, enhancing their persistence in the TME, and developing effective combination therapies, continue to shape future research directions [35, 67]. Overcoming these obstacles through innovative research and development will be crucial for fully realizing the therapeutic potential of CAR-M Φ

Table 2 Differences between CAR-M Φ , CAR-T, and CAR-NK therapies in treating solid tumors

Aspect	CAR-M Φ	CAR-T	CAR-NK
Mechanism of Action	Phagocytosis of tumor cells; secretion of pro-inflammatory cytokines; antigen presentation.	Direct cytotoxicity through antigen-specific T cell activation.	Direct cytotoxicity; release of cytolytic granules; ADCC.
Efficacy in Solid Tumors	Promising, especially in modulating the TME and overcoming immunosuppression.	Limited efficacy due to immunosuppressive TME, difficulty in tumor infiltration, and antigen escape.	Emerging efficacy; faces challenges like CAR-T but with the added benefits of innate targeting mechanisms.
Challenges	Identifying specific tumor antigens for targeting; managing CRS.	Immunological barriers like T-cell exhaustion, antigen loss variation, and immunosuppressive TME.	Overcoming immunosuppressive TIME; ensuring persistence and sustained activity in the hostile TME.
Potential Benefits	Better infiltration into tumors; ability to remodel the TME; potential for sustained antitumor immunity.	High specificity and potency in hematological malignancies; potential for rapid and complete responses.	Lower risk of causing GVHD; potential for quicker and more natural immune response.
Clinical Application	Early clinical trials showing promising results; potential for use in combination therapies.	Well-established in certain hematologic cancers; expanding into trials for solid tumors.	Fewer clinical trials than CAR-T; potential for combination with other immunotherapies for solid tumors.

and broadening their clinical application across diverse cancer types [32]. Addressing these issues through continued research and clinical trials is essential for advancing CAR-MΦ therapy from a promising experimental approach to a robust, clinically viable treatment option for cancer [30].

Tumor microenvironment interaction

Immunosuppressive TME

The TME significantly impacts the efficacy of adoptive cell therapies such as CAR-T and CAR-NK therapies. The TME’s complex array of cellular and molecular components creates a hostile environment that challenges the therapeutic success of these innovative cancer treatments [38, 69]. Figure 2 illustrates the interactions of various

immune cells within the TME and their mechanisms for targeting cancer cells.

The immunosuppressive nature of the TME notably hinders the effectiveness of both CAR-T and CAR-NK cells [8, 84]. While CAR-T cells have achieved remarkable success in hematologic cancers, their transition to treating solid tumors is fraught with difficulties due to substantial physical and biochemical barriers. These barriers include dense extracellular matrices that impede cell infiltration and various immunosuppressive cells and cytokines that restrict access to tumor cells and promote T-cell exhaustion, reducing their cytotoxic functions [5, 69].

Similarly, despite their innate ability to recognize and kill tumor cells without prior sensitization, CAR-NK cells




Fig. 2 Tumor Microenvironment Interaction. This figure illustrates the interactions of various immune cells within the TME and their mechanisms for targeting cancer cells. The top row includes legends for different cell types. The central section depicts a dense network of cancer cells interspersed with various immune cells within the TME, highlighting stimulatory cytokines, including TNF, IL-1, IL-6, IL-12, and IL-18 that enhance immune responses, and inhibitory cytokines such as TGF-β, IL-4, and IL-10 that suppress immune responses. CAR-T cells attack cancer cells by releasing granzymes and perforin, leading to cell death. CAR-NK cells kill cancer cells through direct cytotoxicity using perforin. CAR-MΦ cells, with their dual role, kill cancer cells by secreting pro-inflammatory cytokines and presenting antigens. The death of cancer cells post-interaction with these CAR cells emphasizes their respective mechanisms of action. This figure underscores the complexity of the TME, and the strategies employed by CAR-T, CAR-NK, and CAR-MΦ cells to overcome immunosuppressive barriers and effectively target cancer cells

encounter limitations within the TME that affect their persistence and cytotoxic activity. The suppressive factors within this environment can deactivate their natural cytotoxic mechanisms and reduce their overall effectiveness against tumors [84, 85].

Efforts to mitigate the effects of the TME on CAR therapies involve consensus-driven and innovative strategies [86, 87]. One common approach is engineering CAR cells to express cytokines that counteract the TME's suppressive nature [45, 88]. For instance, incorporating genes that encode stimulatory cytokines such as IL-12 or IL-15 aims to maintain their antitumor activity within this challenging environment [89, 90].

The use of checkpoint inhibitors alongside CAR therapies is also gaining traction. These inhibitors can block the pathways tumors use to suppress immune responses, potentially rejuvenating exhausted CAR-T cells and boosting their functionality within the TME [91, 92].

Overcoming the physical barriers within the TME is crucial for the success of these therapies [93, 94]. Innovations such as enzymatic degradation of the extracellular matrix and employing nanoparticles for more effective delivery of CAR cells are being explored to enhance their infiltration and persistence in tumor sites [95, 96].

Despite significant advances, substantial gaps remain in understanding how to adapt CAR therapies effectively for solid tumors [67, 68, 70]. Questions persist about the optimal design of CAR constructs to improve their affinity for antigens and resistance to immunosuppressive cytokines [15, 97]. Furthermore, understanding the long-term effects of using stimulatory cytokines within CAR constructs on the systemic immune response and patient safety is crucial [12, 98].

As research continues to evolve, filling these gaps will be vital for enhancing the clinical applicability and success of CAR therapies in treating solid tumors. This ongoing exploration is critical to improving outcomes for patients facing these challenging conditions [67, 99].

CAR-M Φ in the TME

CAR-M Φ offers a transformative strategy in the evolution of adoptive cell therapies, targeting the intricate dynamics of the TME [100]. These engineered macrophages aim to reprogram tumor-associated macrophages (TAMs), which tumors typically manipulate to support cancer growth and suppress immune responses [13, 101].

By integrating CAR constructs into macrophages, researchers aspire to transform these generally suppressive immune cells into potent anti-tumor agents [32]. CAR-M Φ is engineered to recognize and destroy tumor cells, potentially reversing the immunosuppressive functions of TAMs and converting them into cells that actively bolster immune responses against the tumor [19, 102]. This approach, however, is subject to significant

debate. While some studies have shown promising results with successful reprogramming leading to tumor regression, others point out the variability of TAM behavior across different tumor types and stages, which can critically affect the outcomes of CAR-M Φ therapies [25, 103].

In addition to reprogramming, CAR-M Φ exhibits a unique potential for beneficial interactions with other immune cells within the TME, such as T cells and NK cells [32]. These interactions, which involve antigen presentation and co-stimulation, could significantly enhance T-cell activation and immune response against tumors. Moreover, the ability of CAR-M Φ to assist NK cells might amplify natural cytotoxic responses against the tumor [104]. Despite these theoretical advantages, the effectiveness and consistency of these interactions in vivo remain a topic of ongoing research, with studies reporting variable outcomes depending on the specific conditions of the TME.

Another promising aspect of CAR-M Φ therapy is its potential synergy with checkpoint inhibitors [105]. These inhibitors, designed to block the proteins that tumors use to shut down immune responses, could be particularly effective when combined with CAR-M Φ , potentially sustaining their activation and tumor-killing ability within the typically immunosuppressive TME [106]. While there is general agreement on the potential benefits of this combination, the empirical evidence is still accumulating, and the optimal strategies for their use continue to be debated.

Despite significant advances, several critical gaps remain in understanding CAR-M Φ 's role within the TME [19, 107]. Questions about the efficacy of TAM reprogramming in various types of solid tumors, the long-term effects of CAR-M Φ therapy on the immune system and tumor dynamics, and the optimal strategies for combining CAR-M Φ therapy with other treatments are crucial for designing a more effective therapeutic strategy [108]. Additionally, understanding how CAR-M Φ navigates the complex regulatory pathways within the immune system and identifying targets to enhance their persistence and efficacy are vital areas needing further exploration [8].

Addressing these gaps through comprehensive research and controlled clinical trials will be essential for advancing CAR-M Φ therapy from a promising experimental approach to a robust, clinically viable treatment option across various cancers. As the field evolves, these efforts will be crucial in optimizing the design and clinical application of CAR-M Φ in oncology [17, 34].

Mechanisms of action

Antigen recognition and activation pathways

CAR-M Φ represents a pivotal shift in cancer immunotherapy, incorporating engineered antigen recognition and activation pathways that distinguish them from

traditional CAR-T and CAR-NK cells. These pathways are crucial for optimizing CAR-M Φ therapies for clinical use [17].

CAR-M Φ is engineered with synthetic receptors targeting specific tumor antigens. These receptors typically include an extracellular antigen-binding domain derived from an antibody's single-chain variable fragment (scFv) connected to intracellular signaling domains that trigger macrophage activation and effector functions upon antigen engagement [34]. The selection of signaling domains remains a subject of considerable debate as researchers seek to optimize configurations that maximize therapeutic benefits without provoking excessive inflammatory responses [8, 19, 109].

Phagocytosis and antigen presentation

The process of tumor cell engulfment by CAR-M Φ involves intricate biological mechanisms [17, 110]. CAR-M Φ , equipped with engineered receptors, binds explicitly to antigens expressed on tumor cells [20, 34]. This binding triggers phagocytic activity, leading to tumor cell internalization and degradation within phagolysosomes [111].

The role of CAR-M Φ in antigen cross-presentation to T cells is central to their functionality, bridging innate and adaptive immunity [112]. After processing, peptides derived from tumor cells are presented via MHC class I molecules, crucial for activating CD8⁺ cytotoxic T cells [113, 114]. This step initiates a broader immune response, allowing T cells to recognize and destroy other tumor cells expressing the same antigens. Debates persist about its efficiency and reliability across different tumor environments [115, 116]. Figure 3 illustrates the various mechanisms through which CAR-M Φ exert their effects within the TME, highlighting their multifaceted approach to tumor eradication [30].

Despite advancements, gaps remain in understanding CAR-M Φ 's phagocytosis and antigen presentation [117, 118]. Questions about the efficiency of tumor cell engulfment within an immunosuppressive TME and factors enhancing this process persist. Additionally, the effectiveness of antigen presentation varies across different patients and tumor types, raising concerns about consistency [119, 120]. The variability of the TME significantly influences CAR-M Φ 's ability to perform effectively, necessitating strategies to overcome these challenges [44, 94].

Addressing these gaps is crucial for CAR-M Φ therapy advancement [33]. Investigating molecular mechanisms that enhance CAR-M Φ and T-cell interactions, optimizing CAR constructs for improved antigen presentation, and devising methods to counteract TME immunosuppressive barriers are essential for future research [88, 121]. A deeper understanding of these processes is vital

for enhancing CAR-M Φ therapy design and clinical application [30, 32, 122].

Cytokine secretion and immune activation

CAR-M Φ impacts cancer immunotherapy by secreting key cytokines that activate and orchestrate the immune response [22, 123]. These cytokines facilitate local and systemic anti-tumor actions, which are crucial for therapeutic success [45, 88, 124].

Key cytokines like IL-12, IL-23, and TNF- α are central to immune modulation [44, 124]. IL-12 activates NK cells and drives CD4⁺ T cells into Th1 cells, which produce IFN- γ , critical for antitumor immunity [125]. IL-23 supports Th17 cell proliferation, which can support or suppress tumor growth depending on the context [126].

The ability of these cytokines to recruit and activate other immune cells is pivotal [19, 39, 124]. Chemokines such as CCL2 and CCL5 attract immune cells to the tumor site, facilitating a robust immune attack, critical for combating tumor heterogeneity and adaptive resistance mechanisms [13, 127, 128].

While the theoretical benefits of cytokine-mediated immune recruitment and activation are acknowledged, debates persist about optimal cytokine levels and types [129, 130]. Excessive cytokine secretion can lead to systemic inflammation and side effects, necessitating careful modulation in CAR-M Φ design [107, 131].

Significant gaps remain in understanding the precise mechanisms of CAR-M Φ cytokine secretion and immune response modulation [132, 133]. Further research is needed to optimize cytokine profiles for therapeutic efficacy and safety, particularly in solid tumors [17, 35].

Phenotypic characterization of CAR-M Φ

Phenotypic characterization of CAR-M Φ is essential to understand their transitions from an M0 (naive) state to an M1 (pro-inflammatory) or M2 (anti-inflammatory) state. The characterization involves assessing the expression of surface markers, cytokine profiles, and functional properties of the engineered macrophages. This incorporation of co-stimulatory domains such as CD28 or 4-1BB in the CAR construct is crucial for macrophage activation, survival, and functionality [19].

Tumor cell killing mechanisms

CAR-M Φ targets cancer cells through direct and indirect mechanisms, showcasing their multifaceted role in cancer therapy [19, 33, 35, 134]. Directly, CAR-M Φ engages in phagocytosis, binding to tumor antigens and initiating tumor cell engulfment and degradation within phagolysosomes [8, 110]. This direct interaction physically removes tumor cells and leads to their breakdown and




Fig. 3 Mechanisms of Action of CAR-M Φ in the TME. This figure illustrates the multifaceted mechanisms through which CAR-M Φ exert their effects within the TME: **(A)** Antigen Recognition and Activation Pathways: CAR-M Φ are equipped with engineered receptors that target specific tumor antigens and intracellular signaling domains, allowing them to switch from an M0 state to an M1 state, which is pro-inflammatory and antitumor. **(B)** TME Remodeling: CAR-M Φ can remodel the TME by releasing pro-inflammatory cytokines that activate exhausted CD8⁺ T cells and other innate immune cells, including NK cells, dendritic cells, eosinophils, and neutrophils. **(C)** Tumor Phagocytosis: When tumor antigens bind to the CAR receptor on the surface of CAR-M Φ , activation signals are generated, leading to tumor phagocytosis. This process includes recognition, activation, engulfment, and elimination within phagolysosomes. **(D)** Transcription Factor Activation and Cytokine Release: CAR-M Φ activation involves transcription factors like NF- κ B, releasing inflammatory cytokines that can activate T cell-mediated immunity against tumors. **(E)** Infiltration of CAR-M Φ in Tumor Cells: CAR-M Φ play vital roles in the TME and, through their direct effects, efficiently eliminate tumor cells by phagocytosis and antigen presentation to CD8⁺ T cells, bridging innate and adaptive immunity. **(F)** Legend: The legend shows the names of immune and tumor cells

destruction, a process noted for its effectiveness in eliminating tumor cells [20, 135].

Indirectly, CAR-M Φ alters the TME through immune modulation. Secreting cytokines and presenting tumor antigens activate and recruit immune cells to the tumor site, enhancing the overall immune response [36, 102]. This recruitment strategy is critical for immediate efficacy and sustaining long-term anti-tumor activity [30, 136].

Despite recognized benefits, gaps remain in understanding CAR-M Φ 's capabilities [19, 22]. Questions about phagocytic efficiency in immunosuppressive environments and optimal cytokine profiles for sustained immune responses persist [17, 35]. Further research is required to optimize CAR-M Φ designs for consistent clinical outcomes [30, 32].

Strategies for enhancing CAR-M Φ efficacy

Advancing through genetic engineering, researchers refine CAR constructs to improve macrophage activation specificity and durability. Innovations like switch receptors and signaling pathway modifications fine-tune anti-tumor effects and control immune responses [137, 138]. These advancements aim to amplify CAR-M Φ 's capabilities while managing off-target effects and systemic toxicity [139, 140].

Exploring combination therapies adds complexity and promise. CAR-M Φ is used alongside other immunotherapeutic agents, like checkpoint inhibitors, designed to overcome TME immunosuppressive barriers and enhance immune response [19, 30, 34, 136]. Combining CAR-M Φ with traditional treatments like chemotherapy and radiation aims to reduce tumor burden and modify the TME for more effective CAR-M Φ activity [36, 88, 141].

Debates continue over the best combination methods, treatment timings, and managing compounded side effects [142, 143]. Substantial gaps remain in understanding the long-term efficacy and safety of these strategies, their impact on patient outcomes, and optimal CAR-M Φ integration with existing treatments. Continuous innovation and rigorous clinical testing are crucial for transitioning CAR-M Φ therapies from experimental approaches to standard cancer care, enhancing direct anti-tumor activities and systemic immune responses [8, 35, 144].

Currently, CT-0508 is safe and feasible to manufacture. Early data demonstrate trafficking, TME modulation, and potential antitumor T cell immunity induction. The study is actively enrolling participants [18]. We look forward to the results from the ex vivo combination sub-study with pembrolizumab and the continued development of CAR-M Φ and CAR-Monocyte therapies.

Technological and manufacturing challenges

Optimization of CAR-M Φ design

The Optimization of CAR-M Φ design is crucial in addressing the challenge posed by the variety of expressions on tumor cells. The presence of varying levels or types of antigens among tumor cells within a tumor mass or across tumors can hinder the effectiveness of CAR-M Φ therapies if the engineered receptors target only specific antigens present in certain tumor cell subsets.

One approach to tackle variability is designing CAR-M Φ that can target multiple antigens simultaneously. By incorporating single-chain variable fragments (scFvs) into the CAR structure, these CAR-M Φ can identify and bind to various TAAs. This multi-targeting strategy increases the chances of reaching a range of tumor cells within heterogeneous tumors [17, 19].

Another strategy involves utilizing scFvs that recognize epitopes shared by an array of tumor cells. These reactive scFvs are created to bind to antigens found across different types of tumors, thereby enhancing the overall effectiveness of CAR Macrophage therapy against heterogeneous tumors [122].

Furthermore, CAR-M Φ can be designed with signaling domains that allow them to adjust their response according to the specific conditions in the TME. For example, including stimulatory molecules, like CD28 or 4-1BB, in CAR design improves macrophage survival, growth, and ability to engulf particles even when encountering different antigen expression levels [8].

Pairing CAR-M Φ therapy with treatments such as checkpoint inhibitors or traditional chemotherapies can tackle the challenge of antigens. By disrupting the immune-suppressing tumor microenvironment and reducing the diversity of tumor cells, these combinations can boost CAR-M Φ effectiveness in targeting a range of tumor cell populations [30, 34].

Moreover, recent progress in epigenetic alterations allows for the modification of tumor cells to display antigens. Techniques like CRISPR/Cas9 can modify tumor cell genomes to make them more identifiable, to CAR-M Φ by standardizing antigen expression throughout the tumor mass [145].

Figure 4 provides an overview of the steps involved in optimizing CAR-M Φ design, including target selection, CAR construction design, and co-stimulatory domain activation pathways.

Ex vivo Manufacturing processes

The ex vivo manufacturing processes for CAR-M Φ are crucial for producing compelling and consistent therapeutic cells. Differentiating and expanding macrophages under controlled conditions involves several vital factors [26]. Initially, monocytes are isolated from PBMCs of the




Fig. 4 Optimization of MΦ Design. **(A)** Target Selection: CAR-MΦ is engineered to target specific tumor-associated antigens. The ectodomain of the CAR is designed to recognize these tumor antigens, ensuring precise targeting and engagement with tumor cells. **(B)** CAR Construction Design: Constructing CAR- MΦ involves inserting genes for the CAR into macrophage cells. The CAR structure includes an antigen recognition domain, a spacer, transmembrane domains, co-stimulatory domains (e.g., CD28 or 4-1BB), and CD3 essential signaling domains. These components are crucial for the activation and function of CAR-MΦ. **(C)** Co-stimulatory Domain and Activation Pathway: Upon activation by IFN- γ and IPS, CAR-MΦ transitions from an M0 (naive) state to an M1 (pro-inflammatory) state. This activation leads to the secretion of inflammatory cytokines such as IL-6, IL-8, IL-12, TNF- α , and TNF- β , which are essential for enhancing the antitumor immune response

patient or donor. These monocytes are then cultured in the presence of specific growth factors, such as M-CSF or GM-CSF, to promote their differentiation into macrophages [146]. Careful monitoring of the culture environment, including temperature, pH, and oxygen levels, is essential to maintain cell viability and functionality [147].

Regarding sourcing macrophages, the choice between autologous and allogeneic sources remains a subject of

ongoing debate. Autologous macrophages, derived from a patient's cells, are favored for their lower risk of eliciting an immune response. Yet, their use is hindered by variability in cell quality and scalability challenges [148, 149]. Conversely, allogeneic macrophages, sourced from donors, offer advantages in scalability and consistency but come with an increased risk of immune rejection and complications like GVHD [19, 38].

Transduction with viral vectors encoding the CAR construct ensures stable expression of CAR on the macrophage surface. The transduction efficiency and expression levels are rigorously evaluated using flow cytometry and molecular techniques [17]. Following transduction, the CAR-M Φ is expanded *in vitro* under optimized conditions supporting their growth and activation, including cytokines like IL-4 and IFN- γ for a pro-inflammatory phenotype conducive to anti-tumor activity. Validating functionality involves assessing antigen recognition, phagocytic ability, and cytokine secretion profile [150].

The protocols for differentiating and expanding macrophages are equally critical. Maintaining controlled conditions promotes the differentiation of progenitor cells into macrophages and ensures these cells appropriately express CAR constructs targeting specific tumor antigens [151]. However, balancing practical CAR expression and maintaining macrophage functionalities present a considerable challenge, often leading to variability in therapeutic outcomes [152]. High levels of CAR expression may enhance antigen recognition and tumor cell killing. However, they can lead to excessive activation and cytokine release, increasing the risk of adverse effects like CRS [142, 153]. To mitigate this, fine-tuning the transduction protocols to achieve an optimal expression level that maximizes therapeutic benefits while minimizing toxicity is necessary [154].

Quality control and standardization are pivotal for the safety and efficacy of CAR-M Φ therapies [155]. Stringent testing protocols assess the purity, potency, and identity of CAR-M Φ batches. Significant gaps exist in standardization processes, particularly concerning the long-term stability and functional consistency of CAR-M Φ post-cryopreservation, and developing universal standards applicable across different manufacturing facilities [156].

These areas of active research and debate illuminate the factors that influence the *ex vivo* production of CAR-M Φ . Addressing these gaps, particularly in standardizing processes and enhancing cell source viability, is crucial for advancing CAR-M Φ therapies from experimental stages to reliable clinical applications [39, 157].

Composition of CT-0508

The CT-0508 consists of autologous macrophages genetically engineered to express a CAR that targets the HER2 expression in solid tumors. This CAR construct, in CT 0508 includes a domain with a scFv, which is specific to the HER2 antigen, and inner signaling domains like CD28 and CD3 ζ that are essential for activating, sustaining, and enhancing the macrophage's functions [141].

To genetically modify the macrophages, a viral vector is employed to insert the CAR gene into their makeup to ensure its presence on the cell surface. These elements showcase the engineering involved in CT 0508 to

enhance the accuracy and efficacy of CAR M Φ therapy, for treating HER2 positive cancers [120].

In vivo reprogramming approaches

The exploration of *in vivo* reprogramming approaches for CAR-M Φ centers on the advancements and challenges associated with nanoparticle-mediated delivery, as well as viral and non-viral gene editing techniques [153].

Nanoparticle-mediated delivery is emerging as a promising method for the targeted transformation of macrophages into CAR-M Φ directly within the patient's body [158]. This technique leverages the unique capabilities of nanoparticles to deliver genetic materials or modulatory substances, especially to macrophages at tumor sites [159]. The precision of this method aims to enhance CAR constructs' integration and functional efficacy *in vivo* [160]. However, there remains a debate over the consistency and safety of nanoparticle delivery, with concerns about off-target effects and the long-term viability of reprogrammed macrophages [161, 162].

Regarding gene editing, viral vectors such as lentiviruses and adenoviruses have demonstrated high efficiency in gene delivery and are widely utilized despite potential risks such as insertional mutagenesis and eliciting immune responses [163, 164].

Due to these risks, the field is somewhat divided on the reliance on viral vectors [165]. In contrast, non-viral methods like CRISPR-Cas9 and transcription activator-like effector nucleases (TALENs) offer a safer alternative, minimizing risks of genomic alterations and adverse immune reactions [166]. These non-viral techniques provide precise editing tools that can enhance the specificity of CAR-M Φ therapy. However, their efficiency and the durability of gene edits in clinical settings continue to be areas of intense investigation [167].

The literature reflects broad consensus on the potential of these *in vivo* reprogramming approaches to revolutionize CAR-M Φ therapies by improving their adaptability and patient-specific efficacy [39]. However, significant gaps in knowledge exist, particularly concerning the long-term effects of *in vivo* reprogrammed CAR-M Φ , the control of gene editing tools within complex tumor environments, and the overall safety of these interventions [8, 30, 39]. Further research is needed to address these challenges, aiming to refine these techniques for safer and more effective clinical applications.

Cost and scalability issues

The transition of CAR-M Φ therapies from experimental to widely available treatments hinges significantly on resolving cost and scalability issues [168]. Current knowledge indicates that the high manufacturing costs stem from intricate cell engineering, complex culture conditions, and the necessity for stringent quality control,

which drive up production expenses [169]. Efforts to address these costs focus on refining manufacturing techniques to enhance the efficiency of cell expansion and gene editing, which could substantially reduce costs.

However, considerable debate remains over the best methods to scale production without compromising the quality and efficacy of CAR-M Φ therapies [170]. Some consensus exists around the potential of automated bioreactors and closed-system cell culture technologies, which promise to increase production capacity and reduce labor costs and contamination risks [34, 171].

Despite these advancements, significant gaps in our understanding of scalable CAR-M Φ production persist [32]. Questions about best standardizing production protocols to ensure consistent quality across different manufacturing sites are still unresolved. Furthermore, the economic viability of scaling up CAR-M Φ therapies to meet global demand, particularly for widespread diseases like cancer, remains a contentious issue [32, 172]. Additional research and development are needed to create cost-effective, scalable manufacturing solutions to support the widespread clinical use of CAR-M Φ therapies.

Regulatory and ethical issues

Regulatory pathways for CAR-M Φ approval

The regulatory approval process for CAR-M Φ is an evolving area that reflects the complexities inherent in bringing new cellular therapies to market [8, 20]. While regulatory frameworks for CAR-T cell therapies provide a foundation, the unique properties of CAR-M Φ necessitate specific considerations. These include their multi-functional role in immune modulation and tissue repair, which could have different implications for patient safety and therapeutic outcomes [30, 173].

Comparatively, the regulatory journey for CAR-T cells has established a precedent that emphasizes stringent evaluation of safety and efficacy. However, CAR-M Φ therapies introduce new variables, such as their phagocytic nature and the broad spectrum of cytokine production, which can affect both tumor and non-tumor tissues [158]. This raises debates about the adequacy of existing regulatory pathways to fully address the nuanced risks associated with macrophage-based therapies.

Controversies emerge particularly around the long-term effects of CAR-M Φ , given their potential to extensively alter immune system dynamics [30, 36]. Regulatory bodies are challenged to develop guidelines that adequately address these concerns while fostering the innovation necessary to realize CAR-M Φ 's therapeutic potential [174]. There is consensus on the need for tailored regulatory approaches that consider the unique biological behaviors of macrophages and their interaction with the TME.

However, significant gaps in knowledge persist, especially regarding the long-term safety and behavior of genetically modified macrophages in humans. These gaps highlight the need for comprehensive preclinical and clinical data to inform regulatory decisions, ensuring that CAR-M Φ therapies are both practical and safe for patients. This section delves into the current state of regulatory processes, emphasizing the ongoing dialogue between researchers, regulators, and the biopharmaceutical industry to refine the approval pathways for these promising but complex therapies.

Safety monitoring and reporting

Safety monitoring and reporting for CAR-M Φ therapies are critical components of their clinical development, given the significant potential for adverse effects such as CRS and other immune-related events. Current frameworks for managing these risks involve protocols adapted from CAR-T cell therapies but tailored to address the unique properties of macrophages. The protocols emphasize early detection and intervention to mitigate the severity of CRS, which remains a primary concern with all CAR therapies [87, 175].

There is a consensus on the need for robust, long-term follow-up to monitor the late-onset effects of CAR-M Φ treatments, which are not fully understood due to these therapies' novel mechanisms of action [176]. The long-term safety profile is especially pertinent given the CAR-M Φ 's ability to alter the TME and potentially affect the immune system in unforeseen ways.

Debates continue over the best practices for safety monitoring, particularly concerning the balance between thorough data collection and the practicality of long-term follow-up in a clinical setting [5, 177]. Questions also persist about the sufficiency of current adverse event reporting systems and whether they adequately capture the range of possible complications, particularly those unique to macrophage-based therapies [160].

Significant gaps in knowledge remain, particularly in how CAR-M Φ interacts with diverse patient immunology over extended periods [142]. Further research is needed to develop and standardize safety monitoring protocols that can effectively track and manage the complex safety profile of CAR-M Φ therapies [178]. These efforts are crucial for ensuring patient safety and facilitating the broader adoption of this promising therapeutic approach in oncology.

Ethical considerations

The integration of CAR-M Φ therapies into clinical practice brings forth complex ethical considerations, particularly regarding patient selection, informed consent, and equitable distribution of these emerging treatments [179]. The current discussion focuses on ensuring ethical

standards in patient selection by establishing scientifically valid and morally sound criteria, aiming to balance the potential benefits and risks associated with CAR-M Φ therapies effectively [180]. The informed consent process is critical, as it must fully educate patients about the experimental nature of CAR-M Φ , potential risks, expected benefits, and possible side effects to ensure decisions are made with adequate knowledge and free of coercion [181].

Debates around access and equity are particularly vigorous, reflecting broader concerns about the availability of cutting-edge medical treatments. There is consensus on the need for strategies to prevent socioeconomic status or geographic location from limiting access to these therapies. However, there is controversy over how best to implement such strategies effectively and relatively [182]. The literature highlights a significant gap in frameworks that could guide equitable access, suggesting that international collaboration is needed to develop policies that facilitate broad and fair distribution without compromising the quality of care.

The ethical implications of CAR-M Φ therapies also extend to long-term societal impacts, such as the potential for altering healthcare paradigms and patient expectations. Current ethical discussions often do not fully address the long-term consequences of widespread CAR-M Φ adoption, indicating a critical area for future research and policy development [183]. As CAR-M Φ technologies advance, ongoing ethical scrutiny will be essential to navigate the complexities of introducing these innovative therapies into routine clinical settings, ensuring they benefit all patients regardless of their background.

Conclusion and future perspectives

This review has critically analyzed the evolving field of CAR-M Φ therapies, identifying groundbreaking advancements and persistent challenges in their development. The synthesis of current research underscores CAR-M Φ as a pioneering approach within cancer immunotherapy, particularly for solid tumors where conventional CAR-T therapies face limitations. Key findings reveal that while CAR-M Φ demonstrates significant potential in modulating the TME and enhancing immune responses, there are substantial gaps in optimizing CAR constructs for maximum specificity and efficacy [35].

Debate continues over the best strategies for CAR-M Φ deployment, with discussions centering on the balance between potent anti-tumor actions and controlling systemic immune reactions to prevent adverse effects. The literature reflects a consensus on the innovative capacity of CAR-M Φ to transform cancer treatment. Yet, it also highlights controversies regarding their long-term

efficacy and safety, which remain inadequately explored in diverse clinical settings [32, 136].

Future research should address these gaps by refining genetic engineering techniques to enhance the precision and stability of CAR-M Φ activation [144]. Expanding clinical trials to include more comprehensive range of tumor types and patient demographics is crucial for understanding the broader applicability of CAR-M Φ therapies [35]. Additionally, ethical considerations regarding patient selection and access to these emerging therapies need a thorough examination to ensure equitable treatment across different populations [183]. By continuing to explore these areas, the field can move towards fully integrating CAR-M Φ into the next generation of standard cancer care, potentially revolutionizing outcomes for patients with previously resistant forms of cancer [19].

Abbreviations

ACT	adoptive cell transfer
ADCC	antibody-dependent cellular cytotoxicity
ALL	acute lymphoblastic leukemia
CAR	chimeric antigen receptor
CAR-M Φ	CAR Macrophage
CAR-NK	CAR natural killer cell
CAR-T	CAR T cell
CRS	cytokine release syndrome
DLBCL	diffuse large B-cell lymphoma
HER2	human epidermal growth factor receptor 2
HLH	hemophagocytic lymphohistiocytosis
ICANS	immune effector cell-associated neurotoxicity syndrome
IFN-g	Interferon gamma
ICI	immune checkpoint inhibitor
IL	interleukin
MAS	macrophage activation syndrome
NK	natural killer
TALENs	transcription activator-like effector nucleases
TAMs	tumor-associated macrophages
TME	tumor microenvironment
TNF- α	tumor necrosis factor-alpha

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40164-024-00549-9>.

Supplementary Material 1

Acknowledgements

The authors would like to thank Professor Qingqing Wang at Zhejiang University for her meticulous review and edits of this manuscript. The figures were created using BioRender.

Author contributions

All the authors collectively conceived and designed this comprehensive review. J.L. and P.C. conducted the literature search and drafted the initial manuscript. W.M. provided supervision, graphics support, editing, and finalized the manuscript. All authors actively participated in the revision of the manuscript, carefully reviewed it, and approved the final version for submission.

Funding

This work was supported by the Joint Funds for the Innovation of Science and Technology, Fujian Province, China (2020Y9097), and the Fujian Provincial Health Technology Project, China (2021GGA019) awarded to P.C.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable to this summary.

Consent for publication

Not applicable to this summary.

Competing interests

The authors declare no competing interests.

Received: 4 June 2024 / Accepted: 30 July 2024

Published online: 05 August 2024

References

- Kelly PN. The Cancer Immunotherapy Revolution. *Science*. 2018;359(6382):1344–5.
- Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. *Int Immunopharmacol*. 2020;85:106628.
- Yao L, Wang Q, Ma W. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance. *Cancers (Basel)* 2023, 15(24).
- Chen Q, Bao Y, Burner D, Kaushal S, Zhang Y, Mendoza T, Bouvet M, Ozkan C, Mineev B, Ma W. Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8(+) T cell immune responses. *Drug Deliv Transl Res*. 2019;9(6):1095–105.
- Chen Q, Lu L, Ma W. Efficacy, Safety, and Challenges of CAR-T-Cells in the Treatment of Solid Tumors. *Cancers (Basel)* 2022, 14(23).
- Chen Q, Guo X, Ma W. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. *Oncol Res*. 2023;32(1):49–60.
- Li H, Song W, Li Z, Zhang M. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. *Front Immunol*. 2022;13:992232.
- Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR-T, CAR-NK to CAR macrophage therapy. *J Exp Clin Cancer Res*. 2022;41(1):119.
- Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. *Biomark Res*. 2022;10(1):12.
- Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, Zhao B, Deng M, Wang W, Mi X, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. *Cell Death Discov*. 2024;10(1):40.
- Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. *Front Immunol*. 2022;13:927153.
- Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, Harris C, Khericha M, Vo KH, Kim M et al. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. *J Exp Med* 2024, 221(6).
- Shao S, Miao H, Ma W. Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs. *Front Immunol*. 2023;14:1295684.
- Xu S, Wang Q, Ma W. Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy. *Cytokine Growth Factor Rev*. 2024;76:12–21.
- Yan T, Zhu L, Chen J. Current advances and challenges in CAR-T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. *Exp Hematol Oncol*. 2023;12(1):14.
- Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, Baradaran B. The current landscape of CAR-T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. *Front Immunol*. 2023;14:1113882.
- Liu M, Liu J, Liang Z, Dai K, Gan J, Wang Q, Xu Y, Chen YH, Wan X. CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro. *Cells* 2022, 11(22).
- Abdou Y, Dees EC, Mortimer JE, Pohlmann PR, Johnson ML, Maziarz RT, Specht JM, Yuan Y, Ueno NT, Angelos M, et al. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. *J Clin Oncol*. 2023;41(16suppl):TP52666–2666.
- Hadiloo K, Taremi S, Heidari M, Esmailzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. *Biomark Res*. 2023;11(1):103.
- Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, Han D, Hong W, Wei W, Tu J. CAR-macrophage: a new immunotherapy candidate against solid tumors. *Biomed Pharmacother*. 2021;139:111605.
- Li SY, Guo YL, Tian JW, Zhang HJ, Li RF, Gong P, Yu ZL. Anti-tumor Strategies by harnessing the phagocytosis of macrophages. *Cancers (Basel)* 2023, 15(10).
- Abdin SM, Paasch D, Morgan M, Lachmann N. CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies. *J Immunother Cancer* 2021, 9(8).
- Na YR, Kim SW, Seok SH. A new era of macrophage-based cell therapy. *Exp Mol Med*. 2023;55(9):1945–54.
- Kciuk M, Yahya EB, Mohamed Ibrahim Mohamed M, Rashid S, Iqbal MO, Kontek R, Abdulsamad MA, Allaq AA. Recent advances in Molecular mechanisms of Cancer Immunotherapy. *Cancers (Basel)* 2023, 15(10).
- Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, Li J, Yao H, Chen K. Role of tumor microenvironment in cancer progression and therapeutic strategy. *Cancer Med*. 2023;12(10):11149–65.
- Paasch D, Meyer J, Stamopoulou A, Lenz D, Kuehle J, Kloos D, Buchegger T, Holzinger A, Falk CS, Kloth C et al. Ex vivo generation of CAR macrophages from hematopoietic stem and progenitor cells for Use in Cancer Therapy. *Cells* 2022, 11(6).
- Xu S, Wang C, Yang L, Wu J, Li M, Xiao P, Xu Z, Xu Y, Wang K. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. *Front Immunol*. 2023;14:1199631.
- Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, Gogas H. Beyond CTLA-4 and PD-1 inhibition: Novel Immune Checkpoint molecules for Melanoma Treatment. *Cancers (Basel)* 2023, 15(10).
- Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. *Mol Cancer*. 2022;21(1):28.
- Yang S, Wang Y, Jia J, Fang Y, Yang Y, Yuan W, Hu J. Advances in Engineered macrophages: a New Frontier in Cancer Immunotherapy. *Cell Death Dis*. 2024;15(4):238.
- Harrasser M, Gohil SH, Lau H, Della Peruta M, Muczynski V, Patel D, Miranda E, Grigoriadis K, Grigoriadis A, Granger D, et al. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC. *Breast Cancer Res*. 2022;24(1):39.
- Li N, Geng S, Dong Z, Jin Y, Ying H, Li H, Shi L. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. *Mol Cancer*. 2024;23(1):117.
- Su S, Lei A, Wang X, Lu H, Wang S, Yang Y, Li N, Zhang Y, Zhang J. Induced CAR-Macrophages as a Novel Therapeutic Cell type for Cancer Immune Cell therapies. *Cells* 2022, 11(10).
- Sloas C, Gill S, Klichinsky M. Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. *Front Immunol*. 2021;12:783305.
- Chen K, Liu ML, Wang JC, Fang S. CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar. *Biomol Biomed*. 2024;24(3):465–76.
- Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. *Nat Rev Drug Discov*. 2022;21(11):799–820.
- Sly LM, McKay DM. Macrophage immunotherapy: overcoming impediments to realize promise. *Trends Immunol*. 2022;43(12):959–68.
- Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. *J Hematol Oncol*. 2023;16(1):97.
- Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A, Li N. CAR-macrophage: an extensive immune enhancer to fight cancer. *EBioMedicine*. 2022;76:103873.
- Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. *Nat Metab*. 2022;4(2):163–9.
- Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, Zhao H, Wei G, Wang Y, Zhang M, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. *Nat Commun*. 2022;13(1):5313.

42. Guo H, Qian L, Cui J. Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome. *Cancer Biol Med*. 2021;19(3):333–42.
43. Davuluri GVN, Chan CH. Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages. *FEBS J*. 2023;290(12):3040–58.
44. Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Macrophages in immunoregulation and therapeutics. *Signal Transduct Target Ther*. 2023;8(1):207.
45. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. *Nat Rev Immunol*. 2022;22(2):85–96.
46. Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR-T-cell therapy and associated prevention and management strategies. *J Exp Clin Cancer Res*. 2021;40(1):367.
47. Yi L, Weng T, Nie P, Zhu L, Gao M, Jia H, Yang S, Li X, Zhang L, Xu Y, et al. Overexpression of interleukin-10 in engineered macrophages protects endothelial cells against LPS-induced injury in vitro. *FEBS Open Bio*. 2022;12(3):605–15.
48. Gomez R, Maakaron J, Baiocchi R. Macrophage activation syndrome Versus Hemophagocytic lymphohistiocytosis: a diagnostic dilemma in a patient with still's Disease and Epstein-Barr Virus Viremia. *J Hematol*. 2019;8(2):68–70.
49. Sztajn bok F, Fonseca AR, Campos LR, Lino K, Rodrigues MCF, Silva RM, de Almeida RG, Perazzo SF, Carvalho MFF. Hemophagocytic lymphohistiocytosis and macrophage activation syndrome: two rare sides of the same devastating coin. *Adv Rheumatol*. 2024;64(1):28.
50. De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schuler GS, Quartier P, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. *Ann Rheum Dis*. 2023;82(6):857–65.
51. Martin-Rojas RM, Gomez-Centurion I, Bailen R, Bastos M, Diaz-Crespo F, Carbonell D, Correa-Rocha R, Pion M, Munoz C, Sancho M, et al. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. *Clin Case Rep*. 2022;10(1):e05209.
52. Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in patients with Relapsed/Refractory diffuse large B cell lymphoma. *Transpl Cell Ther*. 2023;29(7):440–8.
53. Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. *Signal Transduct Target Ther*. 2021;6(1):367.
54. Abdin SM, Paasch D, Lachmann N. CAR macrophages on a fast track to solid tumor therapy. *Nat Immunol*. 2024;25(1):11–2.
55. Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Ingelfield J, Dulau-Florea A, Ceppi F, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CART cells. *Blood*. 2021;138(24):2469–84.
56. Dong X, Fan J, Xie W, Wu X, Wei J, He Z, Wang W, Wang X, Shen P, Bei Y. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. *Br J Cancer*. 2023;129(3):551–62.
57. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. *Front Immunol*. 2023;14:1188049.
58. Villanueva MT. Macrophages get a CAR. *Nat Rev Cancer*. 2020;20(6):300.
59. Wu Y, Huang Z, Harrison R, Liu L, Zhu L, Situ Y, Wang Y. Engineering CAR T cells for enhanced efficacy and safety. *APL Bioeng*. 2022;6(1):011502.
60. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. *Nat Rev Clin Oncol*. 2023;20(6):359–71.
61. Fu W, Lei C, Ma Z, Qian K, Li T, Zhao J, Hu S. CAR macrophages for SARS-CoV-2 immunotherapy. *Front Immunol*. 2021;12:669103.
62. Xu X, Huang S, Xiao X, Sun Q, Liang X, Chen S, Zhao Z, Huo Z, Tu S, Li Y. Challenges and clinical strategies of CAR-T-Cell therapy for Acute Lymphoblastic Leukemia: overview and developments. *Front Immunol*. 2020;11:569117.
63. Giorgioni L, Ambrosone A, Cometa MF, Salvati AL, Magrelli A. CAR-T state of the Art and Future challenges, a Regulatory Perspective. *Int J Mol Sci* 2023, 24(14).
64. Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, Chauhan R, Dagar M, Mirza S, Bagga P, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. *J Transl Med*. 2023;21(1):449.
65. Wang A, Lv T, Song Y. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer. *Cell Immunol* 2023, 391–2:104760.
66. Wang C, Wang J, Che S, Zhao H. CAR-T cell therapy for hematological malignancies: history, status and promise. *Heliyon*. 2023;9(11):e21776.
67. Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. *Cancer Cell Int*. 2024;24(1):133.
68. Rojas-Quintero J, Diaz MP, Palmer J, Galan-Freyre NJ, Morillo V, Escalona D, Gonzalez-Torres HJ, Torres W, Navarro-Quiroz E, Rivera-Porras D et al. Car T cells in solid tumors: overcoming obstacles. *Int J Mol Sci* 2024, 25(8).
69. Kankeu Fonkoua LA, Sirpillio O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. *Mol Ther Oncolytics*. 2022;25:69–77.
70. Guzman G, Pellot K, Reed MR, Rodriguez A. CAR T-cells to treat brain tumors. *Brain Res Bull*. 2023;196:76–98.
71. Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M. CAR-NK cells for cancer immunotherapy: recent advances and future directions. *Front Immunol*. 2024;15:1361194.
72. Zhang B, Yang M, Zhang W, Liu N, Wang D, Jing L, Xu N, Yang N, Ren T. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside. *Cell Death Dis*. 2024;15(1):50.
73. Moscarelli J, Zahavi D, Maynard R, Weiner LM. The Next Generation of Cellular Immunotherapy: chimeric Antigen receptor-natural killer cells. *Transpl Cell Ther*. 2022;28(10):650–6.
74. Shang J, Hu S, Wang X. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies. *Exp Hematol Oncol*. 2024;13(1):21.
75. Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent advances in solid tumor CAR-T cell therapy: driving Tumor cells from Hero to zero? *Front Immunol*. 2022;13:795164.
76. Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. *Cell Mol Immunol*. 2024;21(4):315–31.
77. Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. *EBioMedicine*. 2020;59:102975.
78. Vu SH, Pham HH, Pham TTP, Le TT, Vo MC, Jung SH, Lee JJ, Nguyen XH. Adoptive NK Cell Therapy - a Beacon of Hope in multiple myeloma treatment. *Front Oncol*. 2023;13:1275076.
79. Li F, Liu S. Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. *Front Immunol*. 2022;13:1083462.
80. Mukhopadhyay M. Macrophages enter CAR immunotherapy. *Nat Methods*. 2020;17(6):561.
81. Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, Nayak D, Kaushik S, Das T, Sa G. Tumor-associated macrophages: an effective player of the tumor microenvironment. *Front Immunol*. 2023;14:1295257.
82. Abdul-Rahman T, Ghosh S, Badar SM, Nazir A, Bamigbade GB, Aji N, Roy P, Kachani H, Garg N, Lawal L, et al. The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review. *Eur J Med Res*. 2024;29(1):124.
83. Huang J, Yang Q, Wang W, Huang J. CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy. *Front Immunol*. 2024;15:1378739.
84. Khawar MB, Sun H. CAR-NK cells: from natural basis to design for kill. *Front Immunol*. 2021;12:707542.
85. Valeri A, Garcia-Ortiz A, Castellano E, Cordoba L, Maroto-Martin E, Encinas J, Leivas A, Rio P, Martinez-Lopez J. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. *Front Immunol*. 2022;13:953849.
86. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. *Nat Rev Clin Oncol*. 2020;17(3):147–67.
87. Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Muller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. *Ann Oncol*. 2021;32(1):34–48.
88. Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. *Mol Cancer*. 2023;22(1):20.
89. Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. *Nat Commun*. 2024;15(1):89.
90. Di Trani CA, Cirella A, Arrizabalaga L, Alvarez M, Bella A, Fernandez-Sendin M, Russo-Cabrera JS, Gomar C, Ardaiz N, Teijeira A, et al. Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R1 and PD-L1 exerts potent anti-tumor

- effects without substantial systemic exposure. *Mol Ther Nucleic Acids*. 2023;33:599–616.
91. Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbazadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC et al. Immune checkpoints and CAR-T cells: the pioneers in Future Cancer therapies? *Int J Mol Sci* 2020, 21(21).
92. Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. *Expert Opin Biol Ther*. 2020;20(6):579–91.
93. Bruni S, Mercogliano MF, Mauro FL, Cordo Russo RI, Schillaci R. Cancer immune exclusion: breaking the barricade for a successful immunotherapy. *Front Oncol*. 2023;13:1135456.
94. Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. *J Biomed Sci*. 2022;29(1):83.
95. Lin Y, Chen Y, Luo Z, Wu YL. Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment. *Nanoscale*. 2024;16(7):3226–42.
96. Zhu C, Wu Q, Sheng T, Shi J, Shen X, Yu J, Du Y, Sun J, Liang T, He K, et al. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. *Bioact Mater*. 2024;33:377–95.
97. Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CART cells to improve clinical outcomes. *J Clin Invest* 2021, 131(2).
98. Uscanga-Palomeque AC, Chavez-Escamilla AK, Alvizo-Baez CA, Saavedra-Alonso S, Terrazas-Armendariz LD, Tamez-Guerra RS, Rodriguez-Padilla C, Alcocer-Gonzalez JM. CAR-T cell therapy: from the shop to Cancer Therapy. *Int J Mol Sci* 2023, 24(21).
99. Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. *Curr Oncol Rep*. 2023;25(5):479–89.
100. Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N, Kleeff J, Liao Q, Wu W. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. *Mol Cancer*. 2023;22(1):28.
101. Khan SU, Khan MU, Azhar Ud Din M, Khan IM, Khan MI, Bungau S, Hassan SSU. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy. *Front Immunol*. 2023;14:1166487.
102. Wang H, Yung MMH, Ngan HYS, Chan KKL, Chan DW. The impact of the Tumor Microenvironment on Macrophage polarization in Cancer Metastatic Progression. *Int J Mol Sci* 2021, 22(12).
103. Moeini P, Niedzwiedzka-Rystwej P. Tumor-Associated macrophages: combination of therapies, the Approach to improve Cancer Treatment. *Int J Mol Sci* 2021, 22(13).
104. Li M, Jiang P, Wei S, Wang J, Li C. The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression. *Front Immunol*. 2023;14:1113312.
105. Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. *Cancer Cell Int*. 2022;22(1):2.
106. Wu Z, Li S, Zhu X. The mechanism of stimulating and mobilizing the Immune System enhancing the Anti-tumor Immunity. *Front Immunol*. 2021;12:682435.
107. Liang Y, Xu Q, Gao Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. *Front Immunol*. 2023;14:1291619.
108. Wang S, Yang Y, Ma P, Huang H, Tang Q, Miao H, Fang Y, Jiang N, Li Y, Zhu Q, et al. Landscape and perspectives of macrophage-targeted cancer therapy in clinical trials. *Mol Ther Oncolytics*. 2022;24:799–813.
109. Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. *Exp Mol Med*. 2024;56(1):32–9.
110. Chen S, Lai SWT, Brown CE, Feng M. Harnessing and enhancing macrophage phagocytosis for Cancer Therapy. *Front Immunol*. 2021;12:635173.
111. Lecoultre M, Dutoit V, Walker PR. Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. *J Immunother Cancer* 2020, 8(2).
112. Qin VM, D'Souza C, Neeson PJ, Zhu JJ. Chimeric Antigen Receptor beyond CAR-T cells. *Cancers (Basel)* 2021, 13(3).
113. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion through loss of MHC Class I Antigen Presentation. *Front Immunol*. 2021;12:636568.
114. Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. *Mol Cancer*. 2023;22(1):194.
115. Meraviglia-Crivelli D, Zheleva A, Barainka M, Moreno B, Villanueva H, Pastor F. Therapeutic strategies to enhance Tumor Antigenicity: making the Tumor detectable by the Immune System. *Biomedicines* 2022, 10(8).
116. Kotsifaki A, Alevizopoulos N, Dimopoulou V, Armakolas A. Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers. *Int J Mol Sci* 2023, 24(20).
117. Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for Cancer Immunotherapy. *Cancer Res*. 2021;81(5):1201–8.
118. Qian Y, Yin Y, Zheng X, Liu Z, Wang X. Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities. *Biomark Res*. 2024;12(1):1.
119. Zhou X, Liu X, Huang L. Macrophage-mediated Tumor Cell phagocytosis: opportunity for Nanomedicine intervention. *Adv Funct Mater* 2021, 31(5).
120. Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, Minn D. Recent advances in CAR-Based solid Tumor Immunotherapy. *Cells* 2023, 12(12).
121. Johnson A, Townsend M, O'Neill K. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. *Cells* 2022, 11(22).
122. Haydar D, Ibanez-Vega J, Crawford JC, Chou CH, Guy CS, Meehl M, Yi Z, Perry S, Laxton J, Cunningham T, et al. CAR T-cell design-dependent remodeling of the Brain Tumor Immune Microenvironment modulates tumor-associated macrophages and anti-glioma activity. *Cancer Res Commun*. 2023;3(12):2430–46.
123. Shen J, Lyu S, Xu Y, Zhang S, Li L, Li J, Mou J, Xie L, Tang K, Wen W et al. Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. *Cell Stem Cell* 2024.
124. Silveira CRF, Corveloni AC, Caruso SR, Macedo NA, Brussolo NM, Haddad F, Fernandes TR, de Andrade PV, Orellana MD, Guerino-Cunha RL. Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications. *Front Immunol*. 2022;13:947648.
125. Ullrich KA, Schulze LL, Paap EM, Muller TM, Neurath MF, Zundler S. Immunology of IL-12: an update on functional activities and implications for disease. *EXCLI J*. 2020;19:1563–89.
126. Gamal W, Sahakian E, Pinilla-Ibarz J. The role of Th17 cells in chronic lymphocytic leukemia: friend or foe? *Blood Adv*. 2023;7(11):2401–17.
127. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes Dev*. 2018;32(19–20):1267–84.
128. Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, Lin L. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. *NPJ Precis Oncol*. 2024;8(1):31.
129. Ramesh P, Shivde R, Jaishankar D, Saleiro D, Le Poole IC. A palette of cytokines to measure Anti-tumor Efficacy of T Cell-based therapeutics. *Cancers (Basel)* 2021, 13(4).
130. Deckers J, Anbergen T, Hokke AM, de Dreu A, Schrijver DP, de Bruin K, Toner YC, Beldman TJ, Spangler JB, de Greef TFA, et al. Engineering cytokine therapeutics. *Nat Rev Bioeng*. 2023;1(4):286–303.
131. Chuang ST, Stein JB, Nevins S, Kilic Bektas C, Choi HK, Ko WK, Jang H, Ha J, Lee KB. Enhancing CAR macrophage efferocytosis Via Surface Engineered lipid nanoparticles targeting LXR signaling. *Adv Mater*. 2024;36(19):e2308377.
132. Aderinto N, Abdulbasit MO, Tangmi ADE, Okesanya JO, Mubarak JM. Unveiling the growing significance of metabolism in modulating immune cell function: exploring mechanisms and implications; a review. *Ann Med Surg (Lond)*. 2023;85(11):5511–22.
133. Khalili S, Zeinali F, Moghadam Fard A, Taha SR, Fazzollahpour Naghibi A, Bagheri K, Shariat Zadeh M, Eslami Y, Fattah K, Asadimanesh N et al. Macrophage-based therapeutic strategies in hematologic malignancies. *Cancers (Basel)* 2023, 15(14).
134. Aminin D, Wang YM. Macrophages as a weapon in anticancer cellular immunotherapy. *Kaohsiung J Med Sci*. 2021;37(9):749–58.
135. Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, Zheng W, Lu Y, Zhang W, Bei Y, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. *Br J Cancer*. 2019;121(10):837–45.
136. Shah Z, Tian L, Li Z, Jin L, Zhang J, Li Z, Barr T, Tang H, Feng M, Caligiuri MA et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. *Cell Stem Cell* 2024.
137. Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-Cell-based gene therapy for cancers: new perspectives, challenges, and clinical developments. *Front Immunol*. 2022;13:925985.

138. Chen Z, Hu Y, Mei H. Advances in CAR-Engineered Immune Cell Generation: Engineering approaches and Sourcing strategies. *Adv Sci (Weinh)*. 2023;10(35):e2303215.
139. Teng F, Cui T, Zhou L, Gao Q, Zhou Q, Li W. Programmable synthetic receptors: the next-generation of cell and gene therapies. *Signal Transduct Target Ther*. 2024;9(1):7.
140. Celichowski P, Turi M, Charvatova S, Radhakrishnan D, Feizi N, Chyra Z, Smicek M, Jelinek T, Bago JR, Hajek R, et al. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. *J Transl Med*. 2023;21(1):197.
141. Schepisi G, Gianni C, Palleschi M, Bleve S, Casadei C, Lolli C, Ridolfi L, Martinelli G, De Giorgi U. The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast Cancer. *Cancers (Basel)* 2023, 15(5).
142. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. *Blood Cancer J*. 2021;11(4):69.
143. Wang H, Tang L, Kong Y, Liu W, Zhu X, You Y. Strategies for reducing toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies. *Int J Mol Sci* 2023, 24(11).
144. Moreno C, Haynie C, Cheever A, Weber KS. Alternative CAR therapies: recent approaches in Engineering chimeric Antigen receptor Immune cells to Combat Cancer. *Biomedicines* 2022, 10(7).
145. Ding S, Liu J, Han X, Tang M. CRISPR/Cas9-Mediated genome editing in Cancer Therapy. *Int J Mol Sci* 2023, 24(22).
146. Nielsen MC, Andersen MN, Moller HJ. Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro. *Immunology*. 2020;159(1):63–74.
147. Hummitzsch L, Berndt R, Kott M, Rusch R, Faendrich F, Gruenewald M, Steinfath M, Albrecht M, Zitta K. Hypoxia directed migration of human naive monocytes is associated with an attenuation of cytokine release: indications for a key role of CCL26. *J Transl Med*. 2020;18(1):404.
148. Lyadova I, Vasiliev A. Macrophages derived from pluripotent stem cells: prospective applications and research gaps. *Cell Biosci*. 2022;12(1):96.
149. Sansonetti M, Al Soodi B, Thum T, Jung M. Macrophage-based therapeutic approaches for cardiovascular diseases. *Basic Res Cardiol*. 2024;119(1):1–33.
150. Gao Y, Ju Y, Ren X, Zhang L, Yin X. Enhanced infection efficiency and cytotoxicity mediated by vpx-containing lentivirus in chimeric antigen receptor macrophage (CAR-M). *Heliyon*. 2023;9(12):e21886.
151. Park TS, Hirday R, Quinn R, Jacob SP, Feldman RA, Bose D, Sharma R, Bharti K. Differentiation of monocytes and polarized M1/M2 macrophages from human induced pluripotent stem cells. *STAR Protoc*. 2024;5(1):102827.
152. Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, Fang Y, Wu X, Xu Y, Li C, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. *J Transl Med*. 2023;21(1):654.
153. Zhang Y, Yang J, Zhang T, Gu H. Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy. *Front Bioeng Biotechnol*. 2023;11:1211687.
154. Sheykhasan M, Ahmadiyeh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpannah H, Dirbazian A, Mahaki H, Manoochehri H, Kalhor N, Dama P. CAR T therapies in multiple myeloma: unleashing the future. *Cancer Gene Ther*. 2024;31(5):667–86.
155. Ramesh P, Hui HYL, Brownrigg LM, Fuller KA, Erber WN. Chimeric antigen receptor T-cells: Properties, production, and quality control. *Int J Lab Hematol*. 2023;45(4):425–35.
156. Song HW, Prochazkova M, Shao L, Traynor R, Underwood S, Black M, Fellowes V, Shi R, Pouzolles M, Chou HC et al. CAR-T cell expansion platforms yield distinct T cell differentiation states. *Cytotherapy* 2024.
157. Moradinasab S, Pourbagheri-Sigaroodi A, Ghaffari SH, Bashash D. Targeting macrophage-mediated tumor cell phagocytosis: an overview of phagocytosis checkpoints blockade, nanomedicine intervention, and engineered CAR-macrophage therapy. *Int Immunopharmacol*. 2022;103:108499.
158. Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. *J Exp Clin Cancer Res*. 2022;41(1):68.
159. Shin S, Lee P, Han J, Kim SN, Lim J, Park DH, Paik T, Min J, Park CG, Park W. Nanoparticle-based chimeric Antigen receptor therapy for Cancer Immunotherapy. *Tissue Eng Regen Med*. 2023;20(3):371–87.
160. Guo Q, Qian ZM. Macrophage based drug delivery: key challenges and strategies. *Bioact Mater*. 2024;38:55–72.
161. Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraiyani T, Vasanthan M, Viktor P, Lakshmaiyana N, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. *Mol Cancer*. 2023;22(1):169.
162. Chuang ST, Conklin B, Stein JB, Pan G, Lee KB. Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications. *Nano Converg*. 2022;9(1):19.
163. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, Zhao C, Zheng Z, Shu Y, Wu X, et al. Adenovirus-mediated gene delivery: potential applications for Gene and cell-based therapies in the New era of Personalized Medicine. *Genes Dis*. 2017;4(2):43–63.
164. Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. *Signal Transduct Target Ther*. 2021;6(1):53.
165. Ghosh S, Brown AM, Jenkins C, Campbell K. Viral Vector systems for Gene Therapy: a Comprehensive Literature Review of Progress and Biosafety challenges. *Appl Biosaf*. 2020;25(1):7–18.
166. Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. *Precis Clin Med*. 2021;4(3):179–91.
167. Balke-Want H, Keerthi V, Cadinanos-Garai A, Fowler C, Gkitsas N, Brown AK, Tunuguntla R, Abou-El-Enein M, Feldman SA. Non-viral chimeric antigen receptor (CAR) T cells going viral. *Immunooncol Technol*. 2023;18:100375.
168. Hu D, Yang R, Wang G, Li H, Fan X, Liang G. Emerging strategies to overcome current CAR-T therapy dilemmas - exosomes derived from CAR-T cells. *Int J Nanomed*. 2024;19:2773–91.
169. Timmins LM, Burr AM, Carroll K, Keefe R, Teryek M, Cantolupo LJ, van der Loo JCM, Heathman TRJ, Gormley A, Smith D, et al. Selecting a cell Engineering Methodology during Cell Therapy Product Development. *Cell Transpl*. 2021;30:9636897211003022.
170. Zhang J, Webster S, Duffin B, Bernstein MN, Steill J, Swanson S, Forsberg MH, Bolin J, Brown ME, Majumder A, et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. *Stem Cell Rep*. 2023;18(2):585–96.
171. Abdin SM, Paasch D, Kloos A, Oliveira MC, Jang MS, Ackermann M, Stamo-poulou A, Mroch PJ, Falk CS, von Kaisenberg CS et al. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia. *J Immunother Cancer* 2023, 11(12).
172. Jin G, Chang Y, Bao X. Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma. *Immunooncol Technol*. 2023;20:100409.
173. Yan L, Li J, Zhang C. The role of MSCs and CAR-MSCs in cellular immunotherapy. *Cell Commun Signal*. 2023;21(1):187.
174. Wills CA, Drago D, Pietrusko RG. Clinical holds for cell and gene therapy trials: risks, impact, and lessons learned. *Mol Ther Methods Clin Dev*. 2023;31:101125.
175. Yang C, Nguyen J, Yen Y. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. *J Biomed Sci*. 2023;30(1):89.
176. Santomaso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of Immune-related adverse events in patients treated with chimeric Antigen receptor T-Cell therapy: ASCO Guideline. *J Clin Oncol*. 2021;39(35):3978–92.
177. Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. *Curr Hematol Malig Rep*. 2023;18(2):9–18.
178. Dulac SO, Viers KL, Wagner JR, Clark MC, Chang B, Gorospe GL, Londrc A, Brown AS, Rosenthal J, Smith EP, et al. Developing and monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. *Biol Blood Marrow Transpl*. 2020;26(8):1386–93.
179. Kourelis T, Bansal R, Patel KK, Berdeja JG, Raje NS, Alsina M, Cohen AD, Siegel DSD, Mailankody S, Htut M, et al. Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. *J Clin Oncol*. 2022;40(16suppl):e20021–20021.
180. Bell JAH, Jeffries GA, Chen CI. Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy. *Blood*. 2023;142(15):1263–70.
181. Frankel PH, Groshen S, Beumer JH, Cleveland L, Kim ES, Karp JE. Ethics and Clinical Research: improving transparency and informed consent in phase I oncology trials. *J Clin Oncol*. 2023;41(12):2155–8.

182. Pepper MS, Alessandrini M, Pope A, Van Staden W, Green RJ. Cell and gene therapies at the forefront of innovative medical care: implications for South Africa. *S Afr Med J*. 2018;109(1):20–2.
183. Faiman B, Khouri J, Williams LS, Anwer F. Ethical challenges in CAR-T slot allocation. *Transpl Cell Ther*. 2023;29(4):215–6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.